Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

41.30SEK
24 Sep 2018
Change (% chg)

-0.30kr (-0.72%)
Prev Close
41.60kr
Open
41.65kr
Day's High
42.95kr
Day's Low
41.00kr
Volume
26,685
Avg. Vol
42,935
52-wk High
81.75kr
52-wk Low
32.10kr

Summary

Name Age Since Current Position

Anna Malm Bernsten

57 2016 Independent Chairman of the Board

Christine Lind

44 2018 President, Chief Executive Officer

Erik Bjork

42 2018 Chief Financial Officer

Christina Herder

57 2017 Executive Vice President Strategic Business Development

Asa Holmgren

53 Executive Vice President Strategic Regulatory Affairs and Market Access

Daniel Eriksson

43 2016 Chief Information Officer

Richard Bethell

55 2016 Chief Scientific Officer

Uli Hacksell

68 2018 Director

Anders Hallberg

73 2012 Director

Lennart Hansson

62 2018 Director

Bjorn Klasson

66 2017 Director, Employee Representative

Stina Lundgren

39 2016 Director, Employee Representative

Bengt Julander

65 2017 Independent Director

Helena Levander

61 2015 Independent Director

Bengt Westermark

73 2017 Independent Director

Biographies

Name Description

Anna Malm Bernsten

Ms. Anna Malm Bernsten has been Independent Chairman of the Board of Directors of Medivir AB since May 3, 2016. She has been Independent Director of the Company since 2006. She is also Chairman of the Remuneration Committee, Member of the Company's Audit Committee, Nomination Committee and R&D Committee. She has knowledge of the life sciences sector and runs her own management and business development company. Anna has extensive experience as a director of listed and unlisted companies and operational experience from leading positions in Pharmacia, Assa Abloy, GE Healthcare Life Sciences, Medivir and Baxter Medical, as well as President and Chief Executive Officer of Carmeda AB. She is currently Chairman of the Board of Directors of the Bjorn Axen and Member of the Board of Directors of Cellavision AB, Pagengruppen and Probi. She was previously Member of the Board of Directors of the Medivir acquired BioPhausia AB. She holds a Master of Science degree in Engineering with a major chemical technology, organic chemistry and analytical chemistry.

Christine Lind

Ms. Christine Lind has been appointed President and Chief Executive Officer of Medivir AB, effective as of April 1, 2017. She has previously served as Executive Vice President Strategic Business Development at the Company since March 1, 2015. Her most recent position was as Vice President, Business Development at LifeCell Corporation in New York, and she also has twelve years of investment banking experience at Merrill Lynch & Co. and Gerard Klauer Mattison & Co. Christine holds Bachelor of Science in Finance and Information Systems at New York University and also has a Master of Business Administration from Columbia Business School.

Erik Bjork

Mr. Erik Bjork has been Chief Financial Officer of Medivir AB since January 3, 2018. He is former CFO for Astra Zeneca Sweden Operations. Before that 11 years with Procter & Gamble, in global finance leadership positions in Switzerland, UK and Sweden. Founded and ran a management consultancy focusing on financial strategy and performance with clients within Life Sciences. Erik has a MSc in Finance from Lund University and a Master of Laws from Lund University.

Christina Herder

Dr. Christina Herder, Ph.D. has been Executive Vice President Strategic Business Development at Medivir Aktiebolag since December 14, 2017. She holds Ph. D. in Physical Chemistry from Royal Institute of Technology and Executive MBA from Stockholm University. She is former CEO of Modus Therapeutics. Prior to that, she was Director, Corporate Development at Sobi. Responsible for building and leading the Project & Portfolio Management function at Biovitrum. She has also been Member of the Boards of PCI Biotech and Idogen.

Asa Holmgren

Ms. Asa Holmgren serves as Executive Vice President Strategic Regulatory Affairs and Market Access at Medivir Aktiebolag. She has been employed at the Company since 2015. She holds M. Sc. in Pharmacy, trained at Uppsala University. She is former Head of Regulatory Affairs at Orexo AB. She has experience from a number of large pharmaceutical companies, including 12 years as Senior Global Regulatory Affairs Director at AstraZeneca, and, in particular, international, strategic duties within Regulatory Affairs. Asa has also worked for AstraZeneca in Canada and Japan.

Daniel Eriksson

Mr. Daniel Eriksson has been Chief Information Officer of Medivir Aktiebolag since 2016. He holds Ph.D. from Coventry University, B.Sc. in Systems Science from Linkoping University. He is former Technical Director for G4S Risk Management, India Country Manager for Hill & Associates, e-Governance advisor for Iraqi authorities, CIO for the UN OPS Kosovo mission, as well as a series of positions with the UN and international organizations in roles relating to IT, security, decision support systems, innovation, and digitalization.

Richard Bethell

Mr. Richard Bethell has been Chief Scientific Officer at Medivir AB since 2016. He has previously been Executive Vice President Research & Development at the Company since 2015. He has been Executive Vice President Discovery Research at the Company since April 22, 2013. He has a background within drug discovery and development, with nearly 25 years of experience from the pharmaceutical industry. He joined the Company from Boehringer Ingelheim (Canada) Ltd., where he was employed as Director of Biological Sciences. He also served as Director of Therapeutic Research at Shire and various positions at Pfizer Global and Group Manager, GlaxoSmithKline. He holds a Doctorate of Philosophy degree in Chemistry from the University of Oxford, the United Kingdom and M.A. in Natural Sciences from Cambridge University.

Uli Hacksell

Dr. Uli Hacksell, Ph.D. has been Director of Medivir Aktiebolag since May 3, 2018. He holds Ph.D. from Uppsala University. He has held senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000-2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University. He is Chairman of the Board of Cerecor Inc., and Member of the Boards of InDex Pharmaceuticals AB, Beactica AB and Uppsala University.

Anders Hallberg

Mr. Anders R. Hallberg has served as Member of the Board of Directors of Medivir AB since May 10, 2012. He is Chairman of the Company’s Research and Development Committee. He has held a professorship in Medicinal Chemistry at Uppsala University’s Faculty of Pharmacy since 1990 and has also held a number of positions as scientific advisor at AstraZeneca and smaller pharmaceutical companies between 1990 and 2006. Prior to this, he was the Head of the Medicinal Chemistry Department at Astra in Lund. Between 2006 and 2011 he was the Vice Chancellor of Uppsala University. He has published over 280 scientific articles, a number of which are on the subject of pharmaceuticals for infectious diseases, and is co-inventor of a number of granted patents. He is Member of the Royal Swedish Academy of Sciences, and the Royal Swedish Academy of Engineering Sciences. He has also been awarded honorary doctorates in Sweden and other countries. He is Member of the Boards of foundations and universities.

Lennart Hansson

Mr. Lennart Hansson has been Director of Medivir Aktiebolag since May 3, 2018. He holds Ph.D. in Genetics from Umea University. He has extensive experience of pharmaceutical and commercial development in senior positions with both biotech and pharmaceutical companies, such as KabiGen AB, Symbicom AB, AstraZeneca, and Biovitrum AB, and as CEO of Arexis AB. Responsible for Industrifonden’s life science operations from 2008 to 2016, and currently working as a senior advisor to the fund on a consultancy basis. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies. He is Member of the Boards of InDex Pharmaceuticals AB, Calliditas Therapeutics AB and Cinclus Pharma Holding AB. Chairman of the Boards of Ignitus AB and Sixera Pharma AB.

Bjorn Klasson

Mr. Bjorn Klasson has been Director, Employee Representative at Medivir Aktiebolag since May 2017. He has been appointed by The Swedish Association of Graduate Engineers. He joined the Company in 1991. He is Distinguished Scientist, Medicinal Chemistry Department. He has been Assoc. Professor at the Dept. of Organic Chemistry, University of Stockholm.

Stina Lundgren

Ms. Stina Lundgren has been Director, Employee Representative at Medivir Aktiebolag since November 2016. She has been Deputy Director since 2013. She has been appointed by the Unionen trade union. She holds Ph.D. in Chemistry from KTH Royal Institute of Technology. She was employed in 2008 as a Senior Research Scientist in the Chemistry Department. She is Associate Principal Scientist, Medicinal Chemistry Department.

Bengt Julander

Mr. Bengt Julander has been Independent Director of Medivir Aktiebolag since May 3, 2017. He is Member of the R&D Committee. He holds Master of Science in Pharmacy and has worked in the pharmaceutical industry since 1978. He has been CEO of Linc AB, which invests in life sciences. Since 1990, he has primarily been active as an investor in and a Member of the Boards of pharmaceutical development companies. He has experience of developing and commercializing products. He is Member of the Boards of Linc AB, Livland Skog AB, Calliditas Therapeutics AB, Proequo AB, Sedana Medical AB, Stille AB and Swevet AB, and a number of smaller companies.

Helena Levander

Ms. Helena Levander has been Independent Director of Medivir AB since May 5, 2015. She holds B.Sc. in Economics & Business Administration from the Stockholm School of Economics. She is also Chairman of Company Audit Committee and Member of Remuneration Committee. She is Founder and now Chairman of the Board of Nordic Investor Services AB. Helena has many years’ experience of the financial and equities market and of corporate governance issues, and her CV includes positions at Neonet, Odin Forvaltning, Nordea Asset Management and SEB Asset Management. She is Member of the Boards of Concordia Maritime AB, Recipharm AB and Stendorren Fastigheter AB, and is a former Member of the Boards of, amongst others, Gant AB, Transatlantic AB, Nordisk Energiforvaltning ASA, Svensk Exportkredit AB (SEK), Bure Equity AB, Mandator AB, Geveko AB, Erik Penser Bankaktiebolag and SBAB Bank AB.

Bengt Westermark

Mr. Bengt Westermark has been Independent Director of Medivir Aktiebolag since May 3, 2017. He is Member of the R&D Committee. He is Professor of Tumor Biology at Uppsala University, the Faculty of Medicine, since 1986. He was Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. He was Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. He has been Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organization, and the European Academy of Cancer Sciences. He has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers. He is Member of the Board of Hamlet Pharma AB and a variety of advisory groups for medical research financing.